Akebia Therapeutics (AKBA) Intangibles (2018 - 2024)

Akebia Therapeutics (AKBA) has 7 years of Intangibles data on file, last reported at $9.0 million in Q3 2024.

• On a quarterly basis, Intangibles fell 80.0% year-over-year to $9.0 million in Q3 2024; TTM through Sep 2024 was $9.0 million, a 80.0% decrease from a year earlier, with the FY2023 full-year figure at $36.0 million, down 50.0% from the prior year.
• Intangibles for Q3 2024 stood at $9.0 million, down from $18.0 million in the prior quarter.
• Over the last five years, Intangibles for AKBA reached as high as $282.1 million in Q1 2020 and fell as low as $9.0 million in Q3 2024.
• Historically, Intangibles has averaged $95.6 million across 5 years, with a median of $90.1 million in 2022.
• Across the five-year window, Intangibles slipped 11.43% in 2020 and plunged 80.0% in 2024, its largest moves.
• Year by year, Intangibles stood at $144.2 million in 2020, then fell by 25.0% to $108.1 million in 2021, then slumped by 33.33% to $72.1 million in 2022, then slumped by 50.0% to $36.0 million in 2023, then sank by 75.0% to $9.0 million in 2024.
• Per Business Quant data, the three most recent Intangibles figures were $9.0 million in Q3 2024, $18.0 million in Q2 2024, and $27.0 million in Q1 2024.